Acute Lymphoblastic Leukemia/Acute Myeloid Leukemia

Latest News

Doctor speaking to a female patient with obesity | Image credit: Studio Romantic - stock.adobe.com
The Impact of High BMI on Outcomes, Treatment Efficacy in ALL

June 18th 2025

High body mass index affects outcomes in acute lymphoblastic leukemia (ALL), highlighting the need for targeted interventions to improve patient survival rates and treatment efficacy.

Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

June 12th 2025

Gene sequencing | Image Credit: RFBSIP - stock.adobe.com
Quality Improvement Project Enhances AML Genomic Testing Efficiency

June 11th 2025

Multiracial group of serious young adults sitting | Image credit: Drobot Dean
ALL Disparities, Treatment Gaps: AYA Patients Face Unique Challenges

June 4th 2025

Stephen Strickland, MD, MSCI | Image credit: SCRI
Durability, Reduced Toxicity of CAR NK Therapy in AML May Aid Curative Treatment

May 13th 2025

More News

Maria Amaya, MD, PhD
August 16th 2024

Real-World Outcomes Not Always Reflected in Clinical Trials: Dr Maria Amaya

Kyle Munz
Maria Amaya, MD, PhD, University of Colorado School of Medicine, explores discrepancies between real-world data and clinical trial outcomes, as well as her experience ensuring the reliability of real-world analysis.
ALL cancer cells in blood flow | Image Credit: © Laszlo - stock.adobe.com
August 15th 2024

Spontaneous Remission in Childhood Cancer Rare but Fleeting

Jared Kaltwasser
A case report suggests vigilance is required even when cancers like acute lymphoblastic leukemia appear to go into remission without explanation.
doc comforting patient | Image Credit: Seventyfour-stock.adobe.com
August 3rd 2024

Blinatumomab Boosts Survival in MRD-Negative BCP-ALL

Jared Kaltwasser
Adding blinatumomab to consolidation chemotherapy for B-cell precursor acute lymphoblastic leukemia (BCP-ALL) in patients without measurable residual disease (MRD) led to improvements in overall and relapse-free survival.
awareness of hematologic disorders | Image Credit: Orawan-stock.adobe.com
July 30th 2024

ActivinA Helps B-ALL Cells by Inducing Extracellular Vesicles

Jared Kaltwasser
A new study suggests inhibiting ActivinA might improve the efficacy of chemotherapy in patients with B-cell acute lymphoblastic leukemia (B-ALL).
pregnant woman who is too hot| Image Credit: Studio Romantic-stock.adobe.com
July 27th 2024

High Ambient Temperatures in Pregnancy Related to Childhood Leukemia Risk

Gayle Turim Dickstein
When the mercury outside ascends too high early in pregnancy, the risk of pediatric acute lymphoblastic leukemia may rise as well; results also show greater impacts on Latino populations.
acute leukemia | Image Credit: GoodIdeas-stock.adobe.com
July 22nd 2024

New Study Highlights Venetoclax Combo Efficacy in ALL

Kimberly Rath, PharmD
This new study evaluates the efficacy of monotherapies and venetoclax combination therapies in different T-cell acute lymphoblastic leukemia (ALL) cell lines.
AML cells | Image credit: Laszlo - stock.adobe.com
July 15th 2024

CPX-351 Effective in AML, Possibly With Reduced Cardiotoxicity vs Standard Anthracyclines

Karen Jacobson-Sive
Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity.
concept of a genetic mutation | Image Credit: © lucadp - stock.adobe.com
July 4th 2024

Certain Low-Prevalence Mutations May Be Strong Drivers in Pediatric ALL

AJMC Contributor
The researchers noted that most genomic analyses have traditionally focused on commonly mutated genes, which can pinpoint mutations occurring most frequently but does not account for the extent to which these mutations impact cancer cell survival and proliferation.
Survey graphic | Image Credit: Tierney-stock.adobe.com
July 1st 2024

In Acute Leukemia, Chance of Response Is Patient’s Top Concern

Jared Kaltwasser
Quality of life was also a top concern among patients when asked about their priorities if they experienced relapse or were refractory to therapy.
AML acronym | Image Credit: Natalya-stock.adobe.com
June 28th 2024

Review of Posttransplant Strategies for AML Relapse Prevention

Kimberly Rath, PharmD
Researchers review the latest developments, challenges, and ongoing research in posttransplant maintenance for acute myeloid leukemia (AML).
concept of home | Image Credit: SewcreamStudio-stock.adobe.com
June 19th 2024

HMA Therapy Translates to More Time at Home for Patients With AML

Jared Kaltwasser
People receiving hypomethylating agent (HMA) therapy spent 33 more days at home than people receiving anthracycline-based therapy in the first year after diagnosis.
conceptual image of therapy | Image Credit: ArtemisDiana-stock.adobe.com
June 13th 2024

Induction Treatment Based on Pharmacogenomics May Address Racial Disparities in AML

AJMC Contributor
Data from this new study suggest that tailoring induction therapy for acute myeloid leukemia (AML) based on cytarabine pharmacogenomic 10–single-nucleotide variant score could better treatment for these young patients, particularly those who are Black.
ALL cancer cells in blood flow | Image Credit: Laszlo-stock.adobe.com
June 5th 2024

Inotuzumab Ozogamicin Plus Dose-Adjusted EPOCH: Promise in R/R B-ALL

Gayle Turim Dickstein
Phase 1 trial results indicate that combining inotuzumab ozogamicin with dose-adjusted EPOCH chemotherapy could offer a safe, well-tolerated, and effective treatment option for patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia or lymphoma (R/R B-ALL).
Radiation word pic | Image Credit: KhengGuanToh-stock.adobe.com
May 30th 2024

Consolidative Radiotherapy a Potential Treatment for Extramedullary AML

Luke Halpern
The treatment showed effectiveness in achieving local control of acute myeloid leukemia (AML) that developed in the eyes of a pediatric patient.
ALL acute lymphoblastic leukemia | Image Credit: © sviatlana - stock.adobe.com
May 26th 2024

Ponatinib, Imatinib Face Off, but Still Room for TKI Improvement in Ph+ ALL

Gayle Turim Dickstein
Interim results of the randomized, phase 3 PhALLCON trial indicate ponatinib’s benefit over imatinib in frontline treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), but questions linger about ponatinib’s long-term safety.
Histological analysis | Image Credit: tilialucida-stock.adobe.com
May 15th 2024

Atypical Marker Expression in T-Cell Acute Lymphoblastic Leukemia/Lymphoma

Kimberly Rath, PharmD
Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without typical immaturity markers but with rare γδ T-cell receptor expression.
MRI head brain scan | Image Credit: © DedMityay - stock.adobe.com
May 7th 2024

Case Report Demonstrates Nuanced Decisions in Treating ALL Relapse With Skull Base Lesion

Jared Kaltwasser
Physicians treated the patient without surgery, although they said the patient’s case is particularly challenging and treatment was ongoing at the time of the report’s writing.
Study Shows Improvements in Posttransplant Outcomes Among Older Patients With AML
May 3rd 2024

Study Shows Improvements in Posttransplant Outcomes Among Older Patients With AML

Kimberly Rath, PharmD
Data highlight substantial improvements in outcomes following allogeneic hematopoietic cell transplantation (allo-HCT) among older patients with acute myeloid leukemia (AML).
Older man smiling with nurse | Image Credit: © Beaunitta Van Wyk/peopleimages.com - stock.adobe.com
April 17th 2024

Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate

Gayle Turim Dickstein
A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
AML| Image Credit: Dzmitry - stock.adobe.com
April 8th 2024

In AML, CAR T-Cell Therapy Has Higher CR Rate After Transplant

Jared Kaltwasser
In this investigation, investigators sought insights into the safety and efficacy of chimeric antigen receptor (CAR) T-cell therapy in acute myeloid leukemia (AML), with a particular focus on how various patient subgroups fared for complete remission (CR).
Blood cells flowing | Image credit: Катерина Євтехова - stock.adobe.com
April 2nd 2024

Revumenib Earns FDA Priority Review in R/R KMT2Ar Acute Leukemia

Jordyn Sava
Revumenib, a first-in-class Menin inhibitor, was granted priority review from the FDA for the treatment of adult and pediatric relapsed or refractory KMT2A-rearranged acute leukemia.
Mom and child with cancer | Image Credit: photographee.eu - stock.adobe.com
April 2nd 2024

Post Treatment, Children With ALL Experience Long-Term Fatigue

Jared Kaltwasser
This new report helps clarify the ways in which the disease—and its treatment—affects the lives of children.
Diagnosis, Treatment Remain Challenges for Chronic Disseminated Candidiasis in Acute Leukemia
March 25th 2024

Diagnosis, Treatment Remain Challenges for Chronic Disseminated Candidiasis in Acute Leukemia

Luke Halpern
A case report of a patient with acute leukemia who developed chronic disseminated candidiasis revealed difficulties in diagnosing and treating the illness.
Concept of FDA approved | Image credit: wladimir1804 - stock.adobe.com
March 19th 2024

FDA Grants Accelerated Approval to Ponatinib Plus Chemotherapy in First-Line Ph+ ALL

Rose McNulty
The FDA has granted accelerated approval to ponatinib (Iclusig) plus chemotherapy for the first-line treatment of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
AML cells | Image credit: Laszlo - stock.adobe.com
March 17th 2024

Research Into Reactive Oxygen Species Could Help Address AML Treatment Resistance

Jared Kaltwasser
Treatment resistance remains a major challenge in the treatment of acute myeloid leukemia (AML), and leveraging actionable therapeutic targets is far from straightforward.
leukemia disease concept | Image credit: chrupka - stock.adobe.com
March 12th 2024

Case Series Highlights Bacillus Cereus Risk in Patients With AML, Neutropenia

Jared Kaltwasser
Introducing ciprofloxacin to their institution’s empiric antimicrobial regimen for patients with AML and prolonged or recurrent neutropenic fevers appeared to reduce the risk of Bacillus cereus infection.
AML representation | Image Credit: Andrey stock.adobe.com
March 6th 2024

Pediatric AML Preclinical Pipeline Boosted by Xenograft Models

Luke Halpern
Developing accurate predictive models for patients with pediatric acute myeloid leukemia (AML) can close the preclinical gap in treatment for the rare disease.
Spongy bone tissue affected by osteoporosis, 3D illustration | Image Credit: © Dr_Microbe - stock.adobe.com
February 26th 2024

Methotrexate—but Not Glucocorticoids—Affects BMD in Patients With ALL

Jared Kaltwasser
The findings add complexity to questions about the long-term impact of acute lymphoblastic leukemia (ALL) therapy.
Doctor holding child's hand with intravenous drip | Image Credit: © New Africa - stock.adobe.com
February 21st 2024

COVID-19–Related Chemotherapy Delays Common in Pediatric Patients With Acute Lymphoblastic Leukemia or Lymphoma

Luke Halpern
Despite the widespread practice of delaying or modifying chemotherapy treatment for patients with COVID-19, the investigators wrote that there are no clear data indicating the benefit of this practice.
Genomic Testing Is Worth the Wait When Balanced Against Cost of the Wrong Therapy
February 14th 2024

Genomic Testing Is Worth the Wait When Balanced Against Cost of the Wrong Therapy

Mary Caffrey
Coverage from the discussion, "Cancer Genomics: The Gateway to Access and Health Equity” on the first day of Patient-Centered Oncology Care 2023.
<123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo